“Chris is a visionary leader who combines expertise in AI with experience in drug discovery and development,” said William F. Feehery, Chief Executive Officer. “His leadership has been instrumental in expanding the adoption of AI-powered biosimulation and virtual trials, helping clients achieve greater success in bringing new medicines to patients faster and with greater confidence.
“Biosimulation combined with generative AI and machine learning is redefining how new medicines are discovered and developed, and is speeding timelines, reducing costs, and improving success rates,” said Bouton. “Leading Certara’s technology strategy to build the industry’s most advanced AI and model-informed drug development platform offers a unique opportunity to advance science and deliver better outcomes for patients worldwide.”
关于Certara
Certara 致力于通过生物模拟软件、技术和服务加速药物研发，改变传统的药物研发方式。其客户包括超 2,400 家生物制药公司、学术机构和来自 70 个国家的监管机构。了解更多信息，请访问 www.certara.com.cn。
Certara 联系人:
Sheila Rocchio
[email protected]
媒体联系人：
Alyssa Horowitz
[email protected]
